NCR300 to prevent AML relapse after transplant
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new treatment called NCR300 to try to keep acute myeloid leukemia from coming back after a stem cell transplant. It may help people who have a high risk of relapse or who still have some leukemia cells left after transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with acute myeloid leukemia (AML).
- You received a stem cell transplant from a donor between 28 and 60 days ago.
- Before your transplant, your doctor said you had a high risk of the leukemia coming back, or a test after transplant found very small amounts of leukemia cells.
- Your body has recovered from side effects of previous treatments.
- You are in generally good health (ECOG score less than 3).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an injection of donor-derived immune cells (called RC1012) to lower the chance of AML coming back after an allogeneic stem cell transplant. It is aimed at people at higher risk of relapse once the transplant is completed.
This trial tests whether adjusting a stem cell transplant (allo-HSCT) based on a marker called MRD (minimal residual disease) improves outcomes for people with a high-risk type of acute myeloid leukemia (AML). It's for those who are newly diagnosed, between 16 and 65, and have early remission after 1 or 2 rounds of chemotherapy.
This trial checks if using advanced tests to find leftover cancer cells before a stem cell transplant can help prevent the disease from coming back. If you have a myeloid blood cancer, you might be able to join.
This trial tests giving a menin inhibitor drug after a stem cell transplant to help prevent acute myeloid leukemia (AML) from coming back. You may be eligible if your AML has certain gene changes and you are planning your first transplant.
This trial tests whether giving specially trained natural killer (NK) cells after a stem cell transplant can help prevent relapse in people with high-risk blood cancers like AML, MDS, or MDS/MPN. You receive one infusion of these cells about a week after your transplant.
This trial tests whether a special immune cell infusion (NK cells) from a half-matched family donor can help keep your AML in remission after initial chemotherapy. It is meant for people who have recently achieved their first remission and are otherwise healthy enough for a second round of chemo.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.